TY - JOUR
T1 - Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women
AU - Scott, Garrett
AU - Yiu, Samuel C.
AU - Wasilewski, Daniel
AU - Song, Jonathan
AU - Smith, Ronald E.
N1 - Funding Information:
Supported by an unrestricted grant from Research to Prevent Blindness, New York, New York, NEI grant EYO3040, and by a Baxter Foundation Junior Faculty Award to Dr. Yiu.
PY - 2005/6
Y1 - 2005/6
N2 - PURPOSE: To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT. RESULTS: The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91%) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months). CONCLUSIONS: Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.
AB - PURPOSE: To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT. RESULTS: The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91%) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months). CONCLUSIONS: Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.
UR - http://www.scopus.com/inward/record.url?scp=20444472723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20444472723&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2004.11.042
DO - 10.1016/j.ajo.2004.11.042
M3 - Article
C2 - 15953447
AN - SCOPUS:20444472723
SN - 0002-9394
VL - 139
SP - 1109
EP - 1110
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 6
ER -